CSI Market
Sign In | Register

Rhythm Pharmaceuticals Inc (RYTM) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RYTM Annual Cash Flow →
Reviewing cash flow figures over time highlights how Rhythm Pharmaceuticals Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-212.04
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue-0.19
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories5.43
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation49.16
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.22
Non Cash Rent Expense-
Mark To Market Revaluation Of Investor Right Obligation And Instrument-
Increase Decrease In Deferred Issuance Costs-
Deferred Rent Expense0.11
Depreciationdepletionandamortizationpropertyandequipmentincludingintangibleassets0.25
Derivative Gain Loss On Derivative Net-
Acquired In Process Research And Development Assets Classified As Operating Activities-
Income taxes0.00
Unrealized Gain (Loss) on Investments0.00
Increase (Decrease) in Accounts Receivable14.33
Increase (Decrease) in Accounts Payable and Accrued Liabilities10.84
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-2.32
Other Working Capital-0.44
Other Noncash Income (Expense)-0.67
Other net0.00
Payments for (Proceeds from) Other Operating Activities82.35
Discontinued operations0.00
Net Cash flow from Operating Activities-53.34
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds71.07
Short-term Investments Acq.0.00
Real Estate Investments0.00
Proceeds From Sale Of Priority Review Voucher-
Milestone Obligation Under License Agreement-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities71.07
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-11.20
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock14.35
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-9.72
Other net0.00
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-6.57
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-53.34
Total Cash Flow11.39
4 historic quarters locked

Sign in to unlock the full Rhythm Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Rhythm Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-052533

Figures are derived from filed reports and may be restated. Historical data is subject to revision.